Mucinex®

FOR THE FIRST TIME

THE USE OF MUCINEX® HAS BEEN STUDIED IN VIVO BEYOND 14 DAYS

REAL-WORLD EVIDENCE DATA GENERATION TRIAL UNDERWAY; PRELIMINARY FINDINGS ARE ENCOURAGING

STUDY OBJECTIVE

Describe real-world clinical use of MUCINEX® (e.g., dose, duration, and tolerability) in patients with stable chronic bronchitis (SCB)*.

STUDY DESIGN

In an open-label, multicenter, single-group study, patients with SCB are using MUCINEX® extended-release tablets (2 x 600 mg guaifenesin) twice daily over a 12-week period, following a 2-week run-in period of no treatment (to establish a baseline).

Study population: Adults ≥40 who meet the definition of SCB.

* SCB defined as: Chronic productive cough for at least 3 months in 2 consecutive years and no acute exacerbations in the previous 4 weeks.

Weekly patient-reported data is being collected using bespoke surveys and the cough and sputum assessment questionnaire (CASA-Q)† instrument, while HCP-reported quantitative data is being collected via electronic case report forms.

ROLE OF GUAIFENESIN

In patients with SCB, guaifenesin loosens mucus in the airways and makes coughs more productive, helping with relief of wet cough and chest congestion.

OUTCOMES MEASURED (INTERIM FINDINGS)

Patients reported their experience with using MUCINEX® relative to the following criteria:[†‡§]

Treatment compliance:

High medication adherence observed for majority of patients throughout the treatment period

Treatment satisfaction:

Most patients were satisfied (extremely and somewhat satisfied) with using MUCINEX® to treat their SCB symptoms

Cough and sputum production via CASA-Q:[†]

Majority of patients reported improvement in their cough and sputum symptoms as well as their related quality of life

Safety and tolerability:

Patients who have completed the 12-week treatment period find the dosage of 1200 mg (2 x 600 mg guaifenesin) BID MUCINEX® extended-release tablets to be well tolerated with minimal adverse events reported and no long-term side effects

FULL STUDY RESULTS PENDING IN 2025

† Cough and sputum assessment questionnaire assesses degree to which cough and phlegm affects the day-to-day quality of life of the surveyed patients.
‡ Interim data based on 72 enrolled participants.
§ Participants received MUCINEX® from Week 3 onwards.

Scan to read abstract publication of the 4-week assessment of cough and sputum symptoms of enrolled patients post-treatment with MUCINEX® (2 x 600 mg guaifenesin).
Presented at the 13th London International Cough Symposium, July 18–19, 2024.